CytomX Therapeutics CTMX EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by CytomX Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare.
The official record: CytomX Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about CytomX Therapeutics's eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is CytomX Therapeutics's EPS (diluted)?
- CytomX Therapeutics (CTMX) reported EPS (diluted) of -$0.10 in Q1 2026.
- How has CytomX Therapeutics's EPS (diluted) changed year-over-year?
- CytomX Therapeutics's EPS (diluted) decreased by 137.0% year-over-year, from $0.27 to -$0.10.
- What is the long-term trend for CytomX Therapeutics's EPS (diluted)?
- Over 3 years (2021 to 2025), CytomX Therapeutics's EPS (diluted) has grown at a -71.9% compound annual growth rate (CAGR), from -$1.80 to -$0.04.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.